EDG-7500 is under clinical development by Edgewise Therapeutics and currently in Phase II for Hypertrophic Cardiomyopathy. According to GlobalData, Phase II drugs for Hypertrophic Cardiomyopathy have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EDG-7500’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

EDG-7500 overview

EDG-7500 (EDG-002) is under development for the treatment of inherited hypertrophic cardiomyopathy (HCM). It is administered through oral route in the form of tablet or suspension. The drug candidate acts by targeting an undisclosed sarcomeric target. 

It was also under development for the treatment of adult neuromuscular disorders, metabolic disorders and heart failure with preserved ejection fraction.

Edgewise Therapeutics overview

Edgewise Therapeutics is a pharmaceutical company that discovers, develops and commercializes of innovative products to treat severe and rare muscle disorders. The company’s product portfolio includes EDG-5506, EDG-5440 and EDG-002. Its products are used in various therapeutic areas such as duchenne, limb-girdle and becker muscular dystrophy, hypertrophic cardiomyopathy, McArdle disease (also known as Glycogen storage disease type V or GSDV) and rare neuromuscular disease. Edgewise Therapeutics collaborates with a network of experts who advise and support its development activities. The company utilizes translatable systems to identify small-molecule precision medicines which regulate key proteins in muscle tissue. Edgewise Therapeutics is headquartered in Boulder, Colorado, the US.

For a complete picture of EDG-7500’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.